The Board is pleased to announce that Grand Pharma (China) Co., Ltd, a subsidiary of Grand Pharmaceutical Group Limited, has recently entered into an equity acquisition agreement with Mitsubishi Tanabe Pharma Corporation (田辺三菱製薬株式会社, MTPC). Pursuant to the agreement, Grand Pharma (China) Co., Ltd will acquire 75.35% equity interest in Tianjin Tanabe Seiyaku Co., Ltd (天津田边制药有限公司, Tianjin Tanabe) after the relevant conditions as agreed are fulfilled.
Tianjin Tanabe is one of the core enterprises of MTPC in China, which is mainly engaged in the production and sales of high-quality originator drugs in the fields of cerebro-cardiovascular, endocrine metabolism, gastrointestinal and other chronic diseases. Tianjin Tanabe has several Good Manufacture Practice of Medical Products (GMP) certified production lines, covering a wide range of dosage forms such as tablets, capsules, granules, injections, etc., with more than 10 products on sale, covering a wide range of chronic disease indications including hypertension, angina pectoris, coronary heart disease, diabetes, gastrointestinal and other chronic diseases. Tianjin Tianbian’s core products, such as Herbesser® (合贝爽®及合心爽®), Anplag®, etc., have been included in many global authoritative clinical guidelines at home and abroad, with clear clinical efficacy and high safety, providing high-quality treatment methods for the growing clinical needs of patients with chronic diseases in China.
